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Background: Up to 40% of women with ovarian cancer have short disease-free inter-
vals due to molecular mechanisms of chemotherapy resistance. New therapeutic strate-
gies are sought. Ovarian cancers are sensitive to radiochemotherapy. The taxane cabazi-
taxel (XRP6258, Jevtana) promotes tubulin assembly and stabilizes microtubules against
depolymerization in cells, acting similarly in mechanism to paclitaxel. Here, sequences of
cabazitaxel-radiation co-administration are tested for drug-alone cytotoxicity and optimal
radiosensitization.
Materials and Methods: SKOV3, OVCAR3, andTOV-112D ovarian cancer cells were admin-
istered cabazitaxel 24 h before (first), 18 h before (second), together (third), or 24 h after
(fourth) a single radiation dose, and then, investigated by clonogenic assay and flow
cytometric assays. Radiation dose-cell survival data were fitted by two-stage multivari-
ate analyses of variance. High-content flow cytometry partitioned cabazitaxel effects into
G2-phase versus M-phase events by DNA content, cyclin A2, and phospho-S10-histone H3
(PHH3). Paclitaxel served as a comparator.
Findings: Cabazitaxel cytotoxicity and radiosensitization were dose dependent. Cabazitaxel
added 24 h before radiation was the most lethal schedule. DNA content measurements
by flow cytometry showed that cabazitaxel-treated cells accumulated in the radiosensi-
tive G2/M 4C DNA complement compartment. Cytometry also showed that surviving
cabazitaxel-induced cell cycle arrested cells resolve the arrest by entering 4C or by 8C
DNA complement cell cycles.
Interpretation:The radiosensitizing effect of cabazitaxel was schedule dependent, due to
cell cycle redistribution, and best when cabazitaxel was given 24 h before radiation. Clinical
trials of administering both cabazitaxel and radiation should be explored in women with
chemoresistant ovarian cancer.
Keywords: cabazitaxel, Jevtana, ovarian cancer, radiation
INTRODUCTION
Despite objective response rates of 60–80% to platinum-based
chemotherapy integrated with maximum cytoreductive surgery
(1), the majority of the 22,240 women diagnosed with advanced-
stage ovarian cancer in the United States in 2013 ultimately will
develop progressive disease and will die of complications of their
cancer. Up to 40% of these women will have a short cancer-
free interval due to platinum-refractory disease recurring within
6 months (2). For platinum-refractory disease, a radiation-taxane
therapeutic strategy may be appealing, stemming from experience
gained in prior phase I clinical trials (3).
Assembly of chromosomes during the G2/M-phase of the cell
cycle leaves cells not only vulnerable to death-provoking DNA
double-strand breaks from ionizing radiation (4, 5), but also ren-
ders them sensitive to “poisons” of the mitotic spindle (6, 7).
The taxane paclitaxel and its synthetic analog docetaxel block
G2/M-phase transition by promoting and stabilizing tubulin poly-
mers. While taxanes have lethal cell effects on their own (8),
supraadditive cytotoxic effects are generally found when tax-
anes precede ionizing radiation (9–12). Radiation-taxane additive
effects are observed when cells are exposed to brief pre-irradiation
(13) or post-irradiation taxane incubations (14). Nevertheless,
controversy exists. Both supraadditive effects (9, 10) and subaddi-
tive effects (15, 16) are noted when irradiated cells are incubated
for ≥24 h in taxane-containing media. Mechanisms of untimely
radiation-induced G1-phase block and M-phase cell cycle arrest
have been put forward as means by which cells may escape
taxane-related cytotoxicity (15, 16). Because of the mixed radiore-
sponsiveness of cancer cells to radiation-taxane combinations,
putative novel taxane and radiation combinations must be sub-
ject to extensive molecular in vitro investigations prior to clinical
trial implementation.
Clinically, women having ovarian cancers that relapse after
platinum and paclitaxel-based chemotherapies have therapeutic
responses to an 8 Gy× 3 fraction stereotactic ablative radiosurgery
(SABR) (17). However, disease progression may occur beyond
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the dosimetric contours of SABR-targeted disease. This brings
to attention the need for a chemotherapeutics with radiosen-
sitizing and outright cytotoxic properties that could be safely
combined with SABR. The novel taxane cabazitaxel (XRP6258,
Jevtana) promotes tubulin assembly and stabilizes microtubules
against depolymerization in cells, acting similarly in mechanism
to paclitaxel (18). Cabazitaxel was selected based on its pre-clinical
activity in cancer cells known to be resistant to taxanes, a proof-of-
concept achieved in clinical studies (19, 20). Pre-clinical data for
cabazitaxel have identified an IC50 ranging 0.003–0.029µmol/L, a
1-h post-infusion peak concentration followed by 6 h therapeutic
range in humans, and triphasic elimination of the drug such that
it possesses a long terminal half life (20, 21). Utilizing these phar-
macokinetic parameters, we specifically tested the hypothesis that
cabazitaxel enhances radiation-related cell lethality by inducing
G2/M-phase cell cycle accumulation prior to radiation exposure.
MATERIALS AND METHODS
CELL CULTURES AND CHEMICALS
Human ovarian cancer cells OVCAR3 [P-glycoprotein multiple
drug resistance transporter 1 (mdr-1) positive, p53-mut (codon
248) (22)], SKOV3 [mdr-1 positive, p53-mut (codon 179) (22)],
and TOV-112D [P-glycoprotein multiple drug resistance trans-
porter 1 (mdr-1) negative and p53-mut (codon 175) (23)] were
obtained from American Type Culture Collection (Rockville, MD,
USA). Amdr-1 transporter may allow cells to evade taxane cytotox-
icity (24). Cultured cells were maintained at 37°C in a humidified
5% CO2 atmosphere using Eagle’s minimum essential medium
(Grand Island, NY, USA), with 10% fetal bovine serum, 1% non-
essential amino acids, and 1% penicillin/streptomycin added. Cells
were plated for 24 h prior to any radiation or drug exposure to
generate exponentially growing cell populations. Chemicals used
were purchased from Sigma (St. Louis, MO, USA) unless otherwise
stated.
RADIATION AND DRUG TREATMENTS
Radiation was delivered using a 137Cs γ-irradiator (JL Shepherd
Associates, San Fernando, CA, USA) at 325 cGy per minute. Cabaz-
itaxel (Jevtana, XRP6258) was an investigational agent provided to
Case Western Reserve University (Cleveland, OH, USA) under an
agreement with Sanofi-Aventis (Bridgewater, NJ, USA). To inter-
fere with mitotic spindle activity (18), cabazitaxel was used at end
concentrations of 0–10µM (25). As a comparator, commercially
available paclitaxel was used as indicated at the clinically relevant
end concentrations of 0–10µM (26). For assays with cell harvest
times greater than 6 h, drug-containing medium was exchanged
for drug-free medium 6 h after the start of the drug.
CELL VIABILITY ASSAYS
Triplicate replicates of 1× 104 OVCAR3, SKOV3, and TOV-112D
cells were incubated in 96-well plates for each indicated cabazitaxel
or paclitaxel dose. Cells either underwent sham irradiation or a
conventional clinical radiation dose (2 Gy) at the start of cabaz-
itaxel or paclitaxel exposure. Six hours after the indicated treat-
ment, exchanges for drug-free medium were done. After 18 h (i.e.,
24 h after the start of drug exposure), cells were re-incubated in
300µL of drug-free medium plus MTT (3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide, 5 mg/mL). Following 3 h
of incubation at 37°C, 96-well plates were analyzed by a spec-
trophotometer (Perkin Elmer, Waltham, MA, USA) for quantified
colorimetric absorbance at an excitation wavelength of 540 nm.
Means and standard errors (SE) reflecting viable cell number were
plotted graphically. Analyses of fitted dose-response curves deter-
mined the amount of drug (IC50) that reduced viable cell number
by 50% of control cells (27).
CLONOGENIC SURVIVAL ASSAYS
Exponentially growing OVCAR3, SKOV3, and TOV-112D cells
were plated in triplicate on 24-well dishes to yield 300 cells
(0, 2, 4, 8 Gy) or 3000 cells (20 Gy) per well. Cells underwent
radiation or radiation with 6 h cabazitaxel (1µM), an end con-
centration guided by human pharmacokinetic data (20). Four
different radiation-cabazitaxel treatments were administered –
cabazitaxel given 24 h before (24 h+, first schedule), or 18 h
before (18 h+, second schedule), or together (0 h, third sched-
ule), or 24 h after (24 h−, fourth schedule) a single radiation
dose (2 or 8 Gy). Surviving colonies (>50 cells) were stained
with 0.1% crystal violet in 70% ethanol 14 days after plat-
ing. Untreated cell cloning efficiency was normalized to 100%.
Cloning efficiency of treated cells was expressed as a propor-
tion of treated control survival. Two-stage multivariate analyses
of variance (MANOVA) statistics analyzed radiation-cabazitaxel
interactions (28, 29). MANOVA statistics (α= 0.05) were com-
puted using statistical software (SPSS 18.0, Chicago, IL, USA).
A survival fraction (SF) ratio of combined radiation-cabazitaxel
treatment (Src) relative to the product of survival after radiation
(Sr) and after cabazitaxel alone (Sc) determined additivity status.
A Src/(Sr× Sc) ratio less than 1 indicates a supraadditive inter-
action; a Src/(Sr× Sc) ratio greater than 1 designates subadditive
interaction.
HIGH-CONTENT FLOW CYTOMETRY FOR CELL CYCLE ANALYSIS
Exponentially growing TOV-112D and SKOV3 cells were plated
on 100 mm dishes to yield 2.0× 106 colonies per dish. To study
cell cycle-related molecular events at the G2/M-phase transition,
cells underwent radiation (0 or 2 Gy) and/or 6 h 1µM cabazitaxel
treatment. Trypsinized cultures were fixed and stained for DNA
content by propidium iodide (PI) for standard flow cytometry or
4,6-diamidino-2-phenylindole (DAPI) with fluorescent antibod-
ies reactive with cyclin A2 and phospho-S10-histone H3 (PHH3)
as described (30, 31). Here, we discuss 4C cells, which are cells with
four genome complements. 4C cells can be stemline G2, or stem-
line M, or 4C G1 cells of endoreduplicated (or bi-nucleate) prog-
eny. Measuring the levels of cyclin A2 and PHH3 allow mapping
of G2 and M cells as well as early (prophase, prometaphase) and
later (metaphase, anaphase) stages of mitosis. Cytometry analyses
were performed on a Beckton Dickinson LSRII flow cytometer
(San Jose, CA, USA) using violet, blue, and red excitation and
standard filter set-up. For PI stained cells, fractions of G1-, S-, and
G2/M-phase cells were calculated using ModFit LT (Verity Soft-
ware House, Topsham, ME, USA). For multi-parameter cell cycle
analyses, sequential region mapping in two parameter space was
performed as before by our group (30) using WinList 7.0 (Ver-
ity). An analytic walk-through example is shown in Figure A1 in
Appendix.
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RESULTS
CABAZITAXEL IMPACT UPON OVARIAN CANCER CELL VIABILITY
Ovarian cancer cell viability was determined by MTT assay.
Figure 1 shows cell viability as a function of escalating concentra-
tion of cabazitaxel or of paclitaxel ranging from 0.025 to 10µM.
A 6 h exposure either of cabazitaxel or of paclitaxel minimally
affected OVCAR3, SKOV3, or TOV-112D cell viability at the low-
est concentrations of each drug (0.025–0.1µM). In OVCAR3 cells,
the IC50 was 0.6µM for cabazitaxel and 0.7µM for paclitaxel. In
SKOV3 cells, the IC50 was 0.6µM for cabazitaxel and 1.0µM for
paclitaxel. In TOV-112D cells, the IC50 was 0.6µM for cabazi-
taxel and 0.6µM for paclitaxel. The response to cabazitaxel and
paclitaxel were similar among the three cell lines. As OVCAR3
and SKOV3 cells are both positive for mdr-1, any subtle differ-
ences in taxane sensitivity between the cell lines possibly may be
related to an as yet untested differential affinity of the drugs to
the mdr-1 transporter. More study on mdr-1 positive cells is war-
ranted. TOV-112D cells lack an mdr-1 transporter and because
of this may be slightly more sensitive to taxane cytotoxicity. We
do acknowledge that MTT cell metabolism viability assays do not
distinguish among drug-related cell death or arrest of cell prolif-
eration, both leading to an overall fewer number of cells capable
of metabolizing the MTT introduced in the assay.
Figure 1 also shows ovarian cancer cell viability after drug
exposure plus 2 Gy radiation, with this data normalized for 2 Gy
radiation effect alone. Across all three cell lines, increase in cabaz-
itaxel concentration substantially enhanced radiosensitivity. Two-
step iterations comparing point-by-point cell viability and overall
curve-fit indicated that radiosensitivity was enhanced more after
cabazitaxel than after paclitaxel (P < 0.01 each, Figure 1). In
OVCAR3 cells, the radiation-drug IC50 was 0.03µM for cabaz-
itaxel and 0.03µM for paclitaxel. In SKOV3 cells, the radiation-
drug IC50 was 0.04µM for cabazitaxel and 0.11µM for paclitaxel.
In TOV-112D cells, the radiation-drug IC50 was 0.1µM for cabaz-
itaxel and 0.5µM for paclitaxel. Looking at the IC50 responses
of radiation-cabazitaxel treatment, subtle differences in sensitiv-
ity may be due either to our observed differences in cell doubling
times (40, 36, and 30 h for OVCAR3, SKOV3, and TOV-112D,
respectively) or to additivity effect.
CABAZITAXEL ADDED BEFORE RADIATION MAXIMIZES OVARIAN
CANCER CELL RADIOSENSITIVITY
Cell survival after radiation or after radiation-cabazitaxel was
established by clonogenic assays (Figure 2). Two escalated end con-
centrations of cabazitaxel (0.1, 1.0µM) were selected for radiosen-
sitization testing based upon our radiation-drug IC50 responses. In
all three cell lines investigated by clonogenic survival, both concen-
trations of cabazitaxel-induced a significant decline in cell survival
over a range of radiation doses (MANOVA P< 0.01 for each
cabazitaxel concentration, compared to radiation alone). Detected
differences in survival between radiation-cabazitaxel (0.1µM) ver-
sus (1µM) did not reach statistical significance in any cell line
(MANOVA P> 0.08). Here, we were most interested in the mag-
nitude of radiosensitization at the 8 Gy dose because this dose of
radiation was of particular clinical interest to our SABR program
(17). At an 8 Gy radiation dose given together with a 6-h 1µM
cabazitaxel exposure, a slightly more than additive interaction was
detected. SF ratios were 0.98 for OVCAR3, 0.85 for SKOV3, and
0.99 for TOV-112D cells.
Our next step explored the effects of 1µM cabazitaxel on the
proportion of cells residing in G2- and M-phases of the cell cycle
by cytometry. To mimic clinical pharmacokinetics of cabazitaxel,
drug-containing media was exchanged for drug-free media at the
6 h time point after initial cabazitaxel exposure. We focused cytom-
etry upon the initial 24 h post-exposure cell cycle kinetics period
because were interested in testing putative, clinical workday fea-
sible radiation-cabazitaxel schedules. Table 1 indicates that 1µM
cabazitaxel at least doubles the number of cells stalled at the G2/M-
phase of the cell cycle 6 h post-exposure. The proportion of cells
G2/M-phase-locked broadens over time and becomes maximal at
the end of the first 24 h. Recovery studies showed slow cycling out
of the G2/M-phase arrest and implicate resolution of the arrest
by entering 4C or 8C DNA complement cell cycles (discussed
below).
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FIGURE 1 | Depicted are cell viability assays (MTT) in OVCAR3, SKOV3, andTOV-112D ovarian cancer cells. Radiation (2 Gy), cabazitaxel, or paclitaxel
treatments are indicated. Means and standard errors are plotted.
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FIGURE 2 | Illustrated are clonogenic survival assays in OVCAR3, SKOV3,
andTOV-112D ovarian cancer cells. Cabazitaxel [black circles (0µM), white
circles (0.1µM), gray circles (1µM)] was added at the start of the assay for
6 h; drug-free medium was exchanged afterward for the duration of the assay.
Mean and standard errors are presented. Fitted linear-quadratic regressions
are plotted.
Table 1 | Redistributed G2/M cell cycle proportion after 6-h 1µM
cabazitaxel exposure (%).
Cell line Hours after cabazitaxela
0 h 6 h 12 h 18 h 24 h
OVCAR3 12 26 37 35 43
SKOV3 13 38 51 50 61
TOV-112D 8 33 47 46 58
aFrom three experiments; standard error <1%.
Then, four schedules of combined radiation-cabazitaxel treat-
ment were investigated by cytometric assay and by clonogenic
assay (Figure 3). Cabazitaxel was given 24 h before (24 h+, first
schedule), 18 h before (18 h+, second schedule), together (0 h,
third schedule), or 24 h after (24 h-, fourth schedule) a single
radiation dose (2 or 8 Gy). The third (0 h) co-administered radia-
tion and cabazitaxel schedule showed no perturbation in cell cycle
progression by cytometry (Figure 3A), and treatment was essen-
tially additive (SF range 0.85–1.25 for all cell lines). Therefore,
the third schedule was arbitrarily assigned as the reference treat-
ment by which other schedules would be compared for optimal
radiosensitization.
The first schedule of 1µM cabazitaxel given 24 h before radi-
ation (24 h+) was supraadditive. Cell cycle analyses indicated
that many cells had become stalled at the G2/M transition 24 h
after cabazitaxel exposure (Figure 3A). 24 h+ cells were signifi-
cantly sensitive to radiation (P < 0.01, compared to 0 h schedule,
Figures 3B,C). SF ratios of 0.77, 0.20, and 0.17 at 2 Gy, and SF
ratios of 0.10, 0.11, and 0.25 at 8 Gy were logged for OVCAR3,
SKOV3, and TOV-112D cells, respectively.
The second schedule of cabazitaxel 1µM given 18 h before radi-
ation (18 h+) was also supraadditive. Cytometry indicated that
18 h after cabazitaxel a lower cell proportion had stopped cell
cycle progression at the G2/M transition (Figure 3A). This could
reflect two phenomena. First, cells originally in G1- or S-phase
at the time of cabazitaxel exposure may have been suspended at
the G2/M transition by this 18 h time point. Alternatively, cells
initially in G2/M could have escaped the cell cycle block by cabaz-
itaxel and now be captured by cytometry in a new G1- or S-phase
state. Still, an 18 h+ schedule invoked high radiation-related cell
kill in each cell line (Figures 3B,C). At 2 Gy, SF ratios were 0.83
for OVCAR3, 0.25 for SKOV3, and 0.53 for TOV-112D cells. At
8 Gy, SF ratios were 0.69 for OVCAR3, 0.27 for SKOV3, and 0.99
for TOV-112D cells. While OVCAR3 and SKOV3 cells retained
supraadditive radiochemosensitivity at the two radiation doses,
TOV-D cells showed less combined radiation-cabazitaxel respon-
siveness at 8 Gy. We put forward that this nearly additive inter-
action likely relates to a lack an mdr-1 transporter in TOV-112D
cells. Absence of an mdr-1 transporter and therefore less efflux of
the drug from the cell possibly enhances cabazitaxel-related cell
kill, lowers an observed Sc, and raises SF. Given ablative radia-
tion (8 Gy) has a substantial negative impact upon TOV-112D cell
survival already, it is not unreasonable to observe a merely addi-
tive effect in these particular cells. On the other hand, data could
support the contention that disrupted apoptosis signaling or dif-
ferential drug to target affinity mitigate the effects here. Further
testing is warranted.
The fourth schedule of radiation followed 24 h later by a 6-h
exposure to cabazitaxel 1µM (24 h−) resulted in mixed subaddi-
tive or additive interactions. For this schedule, cytometry detected
only minimal perturbations in cell cycle proportions at the start
of cabazitaxel exposure (Figure 3A). In lower cytometry chan-
nel numbers, PI-signal indicated that some cells had lost DNA and
remained damaged at this 24 h post-irradiation time point. Within
6 h, cabazitaxel-induced a modest rise in G2/M block, with this
effect most pronounced in the relatively quick cycling TOV-112D
cells (30 h doubling time) as compared to OVCAR3 (40 h dou-
bling time) and SKOV3 (36 h doubling time). Clonogenic assays
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FIGURE 3 | Cell cycle analyses are depicted after 6 h 1µM cabazitaxel
exposure alone in OVCAR3, SKOV3, andTOV-112D ovarian cancer cells
(A). Cabazitaxel was given 24 h before (24 h+, first schedule), 18 h before
(18 h+, second schedule), together (0 h, third schedule), or 24 h after (24 h−,
fourth schedule). Corresponding clonogenic survivals for 1µM cabazitaxel
preceding (24 or 18 h−), together (0 h) or after (24 h+) radiation are graphically
presented for 2 Gy (B) or 8 Gy (C) irradiation. Means and standard errors are
shown. Stars indicate significance at P <0.01.
revealed modest cytotoxicity attributable to a 24 h− schedule, but
less so as compared to the first (24 h+) and second (18 h+) sched-
ules. When assessing a combined 24 h− schedule for radiation-
cabazitaxel interactions, it may be the case that death-provoking
DNA damage unrepaired after radiation and lethal stabilization of
mitotic spindles after cabazitaxel sequentially may not overlap to
result in synergistic cytotoxicity. OVCAR3 cells showed a mixed
subadditive SF ratio of 1.29 at 2 Gy but a more than additive SF
ratio of 0.69 at 8 Gy. The mixed responsiveness to a radiation
then cabazitaxel treatment n OVCAR3 cells may be due to a yet
to be explained greater sensitivity to cabazitaxel alone (see also
Figure 1). SKOV3 cells showed supraadditive SF ratios of 0.48 at
2 Gy and 0.27 at 8 Gy. TOV-112D cells exhibited a more than addi-
tive interaction at 2 Gy with a SF ratio of 0.79, but a subadditive
interaction at 8 Gy with a SF ratio of 1.11. Mixed responsiveness in
TOV-112D cells may be related to a greater sensitivity to ablative
(≥8 Gy) radiation alone (see also Figure 2).
RESOLUTION OF G2/M CELL CYCLE ARREST INDUCED BY CABAZITAXEL
Drug-induced biologic effects as a function of the cell cycle may be
monitored by DNA content flow cytometry and readily distinguish
cell proportions residing in the G1 and S phases of the cell cycle.
But cells with four genome complements (4C cells) can exist in
G2, M, or 4C G1 phases that results from either endoreduplication
or failure to undergo cytokinesis, giving rise to a bi-nucleate cell
cycle. To explore the effects of cabazitaxel at the G2/M transition,
we employed multi-parameter analysis using immunodetection
of DNA content, cyclin A2 as an indicator of early mitosis, and
phospho-S10-histone H3 whose elevated expression during the
decline of cyclin A2 maps late mitosis.
Figure 4 depicts the 24 h (t24), 48 h (t48), and 72 h (t72) cell
cycle data for untreated and 1µM cabazitaxel-treated SKOV3 and
TOV-112D cells. As compared to untreated SKOV3 cells at 24 h,
cabazitaxel-treated SKOV3 cells show accumulation at a 4C G2-
phase indicated by intense cyclin A2 signal (e.g., thin arrow). There
is also a substantial M-phase arrest as marked by intense PHH3
signal (e.g., thick arrow). The presence of 4C G1 SKOV3 cells
as the predominant interphase population at 48 h and at 72 h
(double arrows), the predominance of 4C M cells at 48 h (thick
double arrows), and the reduction of 4C M cells at 72 h suggests
that the cabazitaxel-induced M-phase arrest is transient. SKOV3
cells resolve the arrest by entering a cell cycle without mitosis or
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FIGURE 4 | High-content flow cytometry data are depicted for SKOV3
andTOV-112D cells. A 6-h cabazitaxel (1µM) exposure was studied;
drug-free medium was exchanged at the 6-h time point. 24 h (t24), 48 h
(t48), and 72 h (t72) after initial cabazitaxel treatment is indicated for each
row of cytometry data. Arrows highlight clusters that represent
accumulation or arrest at 4C G1 (thin arrow); 4C M (thick arrow, thick double
arrow); 4C G1 (thin double arrow); 4C→8C and 8C→16C cycling
populations (*thin arrows).
cytokinesis (4C→ 8C or 8C→ 16C). Cytometry analyses of TOV-
112D cells shows similar outcomes, but TOV-112D cells move
efficiently through higher order (8C or 16C) cell cycles (∗thin
arrows).
Radiation (2 Gy) when added to 1µM cabazitaxel treatment did
not change the cabazitaxel effects reflected by cyclin A2 or PHH3
in SKOV3 cells. However, the presence of sub G1 events indicating
fragmented DNA (and lethal cell events) appears enhanced in the
irradiated SKOV3 cells. By comparison, irradiated TOV-112D cells
showed 4C G2 arrest at 24, 48, and 72 h, a profound 4C G1 arrest
at 48 h and at 72 h, and a mitotic arrest at 24 and 48 h that is linked
to lower PHH3 levels. The latter finding indicates that the two cell
lines are responding differently at the molecular level, and fur-
ther partitioning of the G2/M-phase could detail such a molecular
“fingerprint.” Taken together, high-content flow cytometry sug-
gests cabazitaxel administered with or without radiation results in
mitotic arrest followed by an escape to a higher order DNA content
cell cycle that may or may not be further damaged by radiation.
A typical mitotic phenotype for microtubule poisons is arrest
at metaphase (cyclin A2 levels are background) or prometaphase
(chromosomes are not attached to a spindle). An expected
cabazitaxel-induced phenotype is residence of cells in a PHH3
high/cyclin A2 low level state (M-LM state). Figure 5 shows high-
content flow cytometry plots of PHH3 level versus cyclin A2 level
at 24 h (t24), 48 h (t48), and 72 h (t72). Effects of 1µM cabazi-
taxel alone and radiation (2 Gy)-cabazitaxel (1µM) are contrasted
with untreated SKOV3 and TOV-112D cells. For both cell lines,
mitotic arrest occurred in a M-LM state (arrows). Other than a
large difference in the number of cells residing in M-LM state,
both cells lines show a cabazitaxel-induced M-phase arrest consis-
tent with activating the spindle checkpoint that is unaffected by
radiation.
Frontiers in Oncology | Radiation Oncology September 2013 | Volume 3 | Article 226 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kunos et al. Cabazitaxel enhances radiochemosensitivity
FIGURE 5 | Mitotic state data are shown for SKOV andTOV-112D cells.
A 6-h cabazitaxel (1µM) exposure was studied; drug-free medium was
exchanged at the 6-h time point. 24 h (t24), 48 h (t48), and 72 h (t72) after
initial cabazitaxel treatment is indicated for each row of cytometry data.
Plots are PHH3 (phospho-S10-histone H3) versus cyclin A2. Mitotic cells
have elevated PHH3 and three mitotic states can be quantified (P4, PM,
M-LM). These are named as previously described (42). Arrows point out
M-LM.
DISCUSSION
Cell cycle phase impact upon cell radiosensitivity has been stud-
ied extensively (5, 32), with attempts to enhance radiosensi-
tivity described by pharmacological manipulation of the cell
cycle (33). In this work, the new taxane cabazitaxel demon-
strated concentration-dependent cytotoxicity and radiosensiti-
zation. While subtle differences in cabazitaxel sensitivity and
radiosensitization were detected, cabazitaxel did show lethal effects
in cells known to evade taxane cytotoxicity. Among four tested
schedules, cabazitaxel added 24 h before radiation enhanced the
lethal effects most. Cytometry confirmed that cabazitaxel-treated
cells accumulated in a radiosensitive G2/M 4C DNA comple-
ment. Cytometry indicated that surviving cabazitaxel-treated cells
resolved arrest by release from the mitotic spindle checkpoint
response and entry into subsequent 4C or 8C cell cycles, in
accordance with prior taxane studies (34, 35).
A precise mechanism by which an augmented G2/M-phase
cell cycle arrest sensitizes cells to radiation is not well under-
stood. An enhanced susceptibility to radiation-induced double-
strand breaks in tightly packaged DNA could partially explain the
radiosensitivity we observed; however, such an explanation can-
not account for the cytotoxic effects of cabazitaxel alone where
mitotic checkpoint responses are likely to be active and protracted
response activation may be lethal as well. Attempted G2/M to G1
traversal in the setting of unrepaired DNA damage is a toxic event,
likely due to activation of mitotic cell death responses and possible
loss of vital genetic material in cell progeny through unrepaired
DNA double-strand breaks (36). It also may be that radiation-
induced, closely situated single-strand breaks are converted to
toxic double-strand breaks over time due to drift of damaged DNA
break ends.
We put forward that stalling of G2/M-phase traversal by
cabazitaxel explains supraadditive interactions when cabazitaxel is
administered 18–24 h before ionizing radiation. This arrest mech-
anism is additionally supported by the resolution of the G2/M-
phase block through either a mitotic spindle checkpoint response
or endoreduplication. Administering radiation and cabazitaxel
treatment together appears additive, as the cell cycle perturbing
effects of cabazitaxel are not apparent for several hours later. Giv-
ing radiation and chasing it 24 h later with cabazitaxel results in
mixed response. The cumulative data suggests that in a radiation-
cabazitaxel therapeutic strategy, the optimal sequence is cabaz-
itaxel first and radiation preferably 24 h later. Pharmacokinetic
and pharmacodynamic experiments in mice have been published
to guide human clinical trials (37). Phase I trials of radiation-
cabazitaxel are needed to clinically confirm or refute radiation-
cabazitaxel sequencing. Other mechanisms of cell cycle manipula-
tion may be at play in our findings – undocumented coordination
of or disruption of intracellular signaling pathways, unrecorded
molecular events related to apoptosis, or possibly unobserved
differential paclitaxel and cabazitaxel affinity for transmembrane
P-glycoprotein transporters.
Paclitaxel is utilized commonly in the clinical management
of women with ovarian cancer (38–40). It is apparent from
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clinical trials that there is a differential response to therapy, with
residual chemorefractory disease harboring no clear-cut mole-
cular signal to explain this difference. A novel taxane such as
cabazitaxel may have desirable cancer cell cytotoxic effects on
its own and effects on the cell cycle that sensitize cells to radi-
ation. It may be envisioned that a second-line radiochemother-
apy strategy could emerge for the management of incom-
pletely responding persistent or recurrent ovarian cancers. Here,
radiosurgery (41) could target and ablate sites of chemorefrac-
tory ovarian cancer while cabazitaxel provides radiosensitization
and independent cytotoxicity. The combination of radiosurgery
and concomitant chemotherapy (i.e., gemcitabine and carbo-
platin) is already being studied in a phase I clinical trial (listed at
http://clinicaltrials.gov/ as NCT01652794). Therefore, we believe
that the enhanced radiosensitivity that taxanes such as cabazitaxel
provides a rationale for testing of cabazitaxel and radiation in short
order.
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APPENDIX
FIGURE A1 |The multi-parametric data are analyzed as follows: the
region R1 gates in singlet cells and excludes all else; the region R2
classifies all mitotic cells. The regions R3 and R4 were used to
determine the median value of integrated DAPI fluorescence signal from
the violet laser (V440-A). These values were used to transform DAPI
fluorescence measurements of G1 and G2/M cells to mean values of
180 and 360, respectively [labeled DNA Content (DAPI)]. R5 and R6 were
used in some samples to remove additional doubles that were missed by
the doublet discriminator (arrow in upper left panel). These are
recognizable by ∼6C content, G1 levels of cyclin A2 signal, and a distinct
cluster. R7 was used to isolate the interphase stem line (2C→4C). R8
and R9 were used to quantify 4C G1 and 8C G2 cells, respectively. The
middle, right panel shows the DNA content histogram for the stem line,
gated on (R1 AND R7 AND NOT R2). This histogram was analyzed by
ModFit LT 3.2 (Verity Software House) to quantify 4C G2 cells (bottom,
left panel). R10 and R11 were used to quantify the bulk of mitotic cells.
These gates exclude early prophase and late telophase/cytokinetic cells.
Finally, R12, R13, and R14 were used to quantify cells in the P4, PM, and
M-LM mitotic states. For further description of mitotic states, see Ref.
(16, 17).
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